Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
103 hedge funds and large institutions have $140M invested in Sanofi Contingent Value Rights in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 13 closing their positions.
60% more capital invested
Capital invested by funds: $87.5M → $140M (+$52.1M)
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
0% more funds holding
Funds holding: 103 → 103 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$1.82M |
| 2 |
Capstone Investment Advisors
New York
|
+$1.18M |
| 3 |
OP
Omni Partners
London,
United Kingdom
|
+$1.11M |
| 4 |
JCI
Jet Capital Investors
New York
|
+$729K |
| 5 |
SCM
Stonehill Capital Management
New York
|
+$553K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$280K |
| 2 |
NGA
New Generation Advisors
Manchester,
Massachusetts
|
-$151K |
| 3 |
BRF
B. Riley Financial
Los Angeles,
California
|
-$144K |
| 4 |
TL
TowerView LLC
New York
|
-$127K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$100K |
GCVRZ Hedge Fund Activity: Q4 2019 in Review
103 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q4 2019, worth a combined $140M — up 60% from $87.5M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new GCVRZ positions and 13 closed out — a net gain of 1 holder — while 11 added to existing stakes and 15 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $1.82M. The largest seller was Wexford Capital, exiting entirely with an estimated $280K sold.
- 103 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $140M of Sanofi Contingent Value Rights stock for Q4 2019, up 60% quarter-over-quarter.
- 14 funds opened new Sanofi Contingent Value Rights positions in Q4 2019 and 13 closed out, a net change of +1 holder.
- The largest Sanofi Contingent Value Rights buyer in Q4 2019 was Farallon Capital Management, an estimated $1.82M added.
- The largest Sanofi Contingent Value Rights seller in Q4 2019 was Wexford Capital, an estimated $280K sold.
Based on aggregated 13F filings for Q4 2019.